"For decades, clinicians have relied on a handful of antifungal classes, with few mechanisms of action and significant limitations due to spectrum of activity, drug toxicities, or drug-drug ...

With the addition of echinocandins to the antifungal spectrum, clinicians should have more options for effective therapy of IC. However, owing to limited prospective data on these newer choices ...

They share common, highly desirable properties with their endogenous AMP predecessors, including a rapid kill time and activity against a broad range of fungal, bacterial and polymicrobial ...